Azitra, Inc. (AZTR) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Azitra, Inc. (AZTR)

Azitra, Inc. (AZTR) relies on a staff of leading microbiologists and dermatozoon experts, expanding its team with clinical trial specialists. The company is developing innovative treatments for eczema, targeting the vast biotechnology market. The share price history based on the EV/EBITDA metric currently stands at 0.00. The business's financial stability is secured through the patenting of unique bacterial platforms for the therapy of chronic skin pathologies.

Azitra Corp - AZTR Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Metric breakdowns and analytics for azitrainc.com (AZTR)

- market price and analyst price targets:
Price Chart Azitra Corp|AZTR - Analyst Median Target
- market capitalization details:
Market Value Azitra Corporation|AZTR - Enterprise Value
- book value of equity indicators:
Book Value per Share Azitra|AZTR - Book Valuation of Business|Market Value to Book Value Ratio azitrainc.com|AZTR - Total Business Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Azitra, Inc.|AZTR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Azitra|AZTR - Company Aggregate Indebtedness|Debts to Book Capitalization Azitra Corporation|AZTR - Long-Term Debt Volume|Company Current Liabilities Azitra|Quick Liquidity azitrainc.com
- financial results and valuation multiples details:
AZTR - Final Profit|Projected Future Earnings Azitra, Inc.|AZTR - P/E Multiple|Projected Price to Earnings Azitra, Inc.|AZTR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Azitra Corporation|AZTR - Operating income before deduction of amortization|Earnings per share for the last twelve months Azitra|AZTR - Earnings per share for the last 12 months|Quarterly EPS earnings growth azitrainc.com|AZTR - Net earnings per share growth this year|Expected earnings per share growth for next year Azitra, Inc.
Fundamental valuation:Azitra Corp AZTR
Product sample of Azitra Inc

This indicator compares Enterprise Value (EV) with EBITDA, allowing for an asset valuation that accounts for debt load. For Azitra, Inc. (AZTR), which is striving for a monopoly in skin bioengineering, an EV/EBITDA ratio including depreciation and debt at 0.00 reflects capitalization efficiency amidst the clinical race. Analysis of this chart helps determine the extent to which the issuer is undervalued relative to US industry benchmarks.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Krystal Corp KRYS|Total Company Value to Operating Income Before Depreciation Ratio Apogee Corp (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Tech|Enterprise Value to Operating Income Before Depreciation SLSN (Solesence Inc.)|EV/EBITDA Multiple DERM|EV/EBITDA Multiple fortebiorx.com (FBRX)|Empro Group - Enterprise Value to EBITDA Ratio|SLGL (Sol-Gel Technologies Ltd) - Company Value to Operating Income Before Depreciation Ratio|Revive Pro Care - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Medicus Pharma Corp MDCX|VRCA (verrica.com) - Enterprise Value to EBITDA Ratio|HOTH: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biofrontera, Inc.|VYNE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SNOA|EV/EBITDA Multiple quoinpharma.com (QNRX)|Dermata Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ELAB|Revance Therapeutics, Inc. - EV/EBITDA Multiple